TRO and hepatocellular carcinoma: More recently, KIAA1114 has been revealed as a distinct and stable marker for CSCs in hepatocellular carcinoma, and, Kiatomab, a mAb specific to KIAA1114, showed therapeutic potential in a murine tumor model, suggesting that KIAA1114 could be applied as a novel target antigen for CSC CAR-T cell therapy [175].